Home » Newsletters » BioWorld Science

BioWorld Science

April 18, 2013

View Archived Issues

Clinical data for AMP-224 presented at AACR meeting

Polymorphisms in NPY and IL1B genes identified as risk factors for vitiligo

FDA approves Sitavig for labial herpes

Innovative 3D renal tissue model developed to investigate human disease and toxicity

IMCgp-100 well tolerated in patients with advanced melanoma

VAL-201 shows promise in animal models of prostate and breast cancer

Achillion begins phase II HCV study of sovaprevir and ACH-3102

Allergan receives complete response letter for Levadex NDA

Ablynx presents in vitro and in vivo data for novel anti-c-Met Nanobody

Merck & Co. synthesizes new FSH-R antagonists for gynecological disorders

Roche discloses novel eIF4E inhibitors for cancer

New JAK1/JAK2 inhibitors divulged by Merck & Co.

Boehringer Ingelheim patents new DPPI inhibitors

Bayer prepares new Mnk1 inhibitors for hyperproliferative diseases

Researchers at GlaxoSmithKline synthesize new mTOR inhibitors

FDA grants Charleston Laboratories' request for pre-IND meeting

Galapagos expands phase IIb trial of GLPG-0634 in rheumatoid arthritis

Clinical trial application submitted to RAC for TT-034

Eisai receives marketing authorization in Japan for vascular embolization device Dc Bead

Nymox's candidate for BPH shows promising sexual function profile in new study

Collegium Pharmaceutical completes study on Oxycodone DETERx

Neuralstem receives FDA approval to conduct phase II stem cell trial for ALS

Taisho seeks Japanese approval of luseogliflozin for type 2 diabetes

Omeros files orphan drug application for OMS-721

Santarus and Pharming report submission of Ruconest BLA to FDA

FDA advisory committee votes in favor of Breo Ellipta for COPD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...